Scleroderma Therapeutics Market To Reach $3.44 Billion By 2030

Scleroderma Therapeutics Market Growth & Trends

The global scleroderma therapeutics market size is expected to reach USD 3.44 billion by 2030, registering a CAGR of 5.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is credited to the availability of various therapies used off-label, such as small molecule therapies including branded, generics, and OTC drugs.

The mix of several indications and drug classes engenders a fragmented market with multiple players. Roche is the dominant company with biologic immunosuppressants, Actemra/RoActemra, Cellcept, and Rituxan contributing majorly to the company’s share. Pfizer and Eli Lilly are the key companies in the market. Over the forecast period, new entrants including Boehringer Ingelheim, Corbus Pharmaceuticals, and Fibrocell will marginally displace the share of established firms in this market.

The on-label market is in the development phase. Supplemental indication approval is one of the most common strategies adopted by market participants. For example, riociguat by Bayer was previously used for PAH and currently, it is under clinical trials for the treatment of SSc-related digital ulcers. There are several other pharmaceutical companies following suit as this strategy favors the pharmaceutical industry in offsetting high development costs and in reaping larger benefits from one molecule already developed and present in the market.

 Request a free sample copy or view report summary: Scleroderma Therapeutics Market Report

Scleroderma Therapeutics Market Report Highlights

• The immunosuppressors segment accounted for the largest share of 27.4% in 2024, and is likely to maintain the dominance throughout the forecast years

• High preference for immunosuppressants owing to the favorable reimbursement scenario associated with this drug class supports its dominant market share

• Systemic scleroderma indication segment accounted for the major market share and will expand further due to use of high-priced immunosuppressants

• The U.S. market accounted for 90.6% share of the North America scleroderma therapeutics market in 2024. Expected label expansions and expected launch of first-in-class therapies coupled with an evolving reimbursement landscape for orphan drugs support continual scleroderma therapeutics market growth

• Europe trails with a lower share as compared to the U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma

Scleroderma Therapeutics Market Segmentation

Grand View Research has segmented the global scleroderma therapeutics market on the basis of drug class, indication, and region:

Scleroderma Therapeutics Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Immunosuppressors

• Phosphodiesterase 5 inhibitors - PHA

• Endothelin Receptor Antagonists

• Prostacyclin Analogues

• Calcium Channel Blockers

• Analgesics

• Others

Scleroderma Therapeutics Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Systemic Scleroderma

  • Morphea

  • Linear

• Localized Scleroderma

  • Diffuse Systemic Sclerosis

  • Limited Cutaneous Systemic Sclerosis Syndrome

Scleroderma Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Scleroderma Therapeutics Market

• F. Hoffman La-Roche Ltd

• Bristol-Myers Squibb Company

• Bayer AG

• Boehringer Ingelheim International GmbH

• Emerald Health Pharmaceuticals

• Sanofi

• Cytori Therapeutics Inc.

• Chemomab

• Corbus Pharmaceuticals Holdings, Inc.

• Calliditas Therapeutics AB.